奥马珠单抗治疗难治性变应性哮喘效果的Meta分析

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (1351 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effectiveness of Omalizumab in patients with refractory allergic asthma. Methods The databases including PubMed, Web of Science, Embase, Cochrane Library, and ScienceDirect were searched by computer, and the retrieval time of each database was from the database establishment to November 2017. Then 2 reviewers screened studies, extracted data, and evaluated the quality of included randomized controlled trials, and Meta-analyses were conducted with RevMan 5.3. Results A total of 12 clinical randomized controlled trials were included. Compared with placebo, Omalizumab treatment was associated with an improved asthma-related quality of life at the end of the stable (RR = 1.56, 95%CI: 1.32-1.85, P ＜ 0.000 01) and steroid dose reduction phases (RR = 1.90, 95%CI: 1.45-2.49, P ＜ 0.000 01). Meanwhile, compared with placebo, Omalizumab therapy showed a significantly increased number of patients with investigator global evaluation of therapy effective rated as excellent or good at the end of both phases (RR = 1.36, 95%CI: 1.25-1.49, P ＜ 0.000 01; RR = 1.48, 95%CI: 1.36-1.61, P ＜ 0.000 01). Besides, Omalizumab reduced the number of patients with severe exacerbations during stable-steroid phase (RR = 0.51, 95%CI: 0.41-0.64, P ＜ 0.000 01). Conclusion The addition of Omalizumab to standard therapy in patients with refractory allergic asthma can improve asthma related quality of life, relieve symptoms and reduce severe asthma exacerbations.

Key words： Refractory allergic asthma Omalizumab Meta analysis Questionnaire of asthma quality of life in adults Investigator global evaluation of therapy effectiveness Severe exacerbations

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MOU Shan ZHANG Wei JIANG Depeng

Cite this article:

MOU Shan ZHANG Wei JIANG Depeng. Effectiveness of Omalizumab for patients with refractory allergic asthma: a Meta analysis of randomized controlled studies[J]. 中国医药导报, 2019, 16(10): 75-79,99.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I10/75

[1] Caruso M，Morjaria J，Emma R，et al. Biologic agents for severe asthma patients：clinical perspectives and implications [J]. Intern Emerg Med，2017，13（2）：155-176.
[2] Busse W，Corren J，Lanier BQ，et al. Omalizumab，anti-IgE recombinant humanized monoclonal antibody，for the treatment of severe allergic asthma [J]. J Allergy Clin Immunol，2001，108（2）：184-190.
[3] Milgrom H，Berger W，Nayak A，et al. Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody（Omalizumab）[J]. Pediatrics，2001，108（2）：E36.
[4] Lee JH，Lee HY，Jung CG，et al. Therapeutic Effect of Omalizumab in Severe Asthma：A Real-World Study in Korea [J]. Allergy Asthma Immunol Res，2018，10（2）：121-130.
[5] Normansel R，Walker S，Milan SJ，et al. Omalizumab for asthma in adults and children（review）[J]. Cochrane Database Syst Rev，2014，13（1）：CD003559.
[6] Vignola AM，Humbert M，Bousquet J，et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis：SOLAR [J]. Allergy，2004，59（7）：709-717.
[7] Finn A，Gross G，Bavel JV，et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma [J]. J Allergy Clin Immunol，2003，111（2）：278-284.
[8] Humbert M，Beasley R，Ayres J，et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy（GINA 2002 step 4 treatment )：INNOVATE [J]. Allergy，2005，60（3）：309-316.
[9] Sthoeger ZM，Eliraz A，Asher I，et al. The Beneficial Effects of Xolair?（Omalizumab）as Add-On Therapy in Patients with Severe Persistent Asthma who are Inadequately Controlled Despite Best Available Treatment（GINA 2002 step Ⅳ）--The Israeli Arm of the INNOVATE Study [J]. Isr Med Assoc J，2007，9（6）：472-475.
[10] Lanier B，Bridges T，Kulus M，et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic（IgE-mediated）asthma [J]. J Allergy Clin Immunol，2009，124（6）：1210-1216.
[11] Kulus M，Hébert J，Garcia E，et al. Omalizumab in children with inadequately controlled severe allergic（IgE-mediated）asthma [J]. Curr Med Res Opin，2010，26（6）：1285-1293.
[12] Jing L，Kang J，Wang CZ，et al. Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma：A Randomized Phase Ⅲ Study [J]. Allergy Asthma Immunol Res，2016，8（4）：319-328.
[13] Holgate ST，Chuchalinw AG，Hebertz J，et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody（omalizumab）in severe allergic asthma [J]. Clin Exp Allergy，2004，34（4）：632-638.
[14] Bardelas J，Figliomeni M，Kianifard，F，et al. A 26-Week，Randomized，Double-Blind，Placebo-Controlled，Multicent er Study to Evaluate the Effect of omalizumab on Asthma Control in Patients with Persistent Allergic Asthma [J]. J Asthma，2012，49（2）：144-152.
[15] Lemansake RF，Nayak A，McAlary M，et al. Omalizumab improves asthma-related quality of life in children with allergic asthma [J]. Pediatrics，2002，110（5）：e55.
[16] Corren J，Kavati A，Ortiz B，et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma：A systematic literature review [J]. Allergy Asthma Proc，2017，38（4）：250-263.
[17] Lai T，Wang S，Xu Z，et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma a systematic review and meta-analysis [J]. Sci Rep，2015，5：8191.
[18] Licari A，Castagnoli R，Denicolò C，et al. Omalizumab in Children with Severe Allergic Asthma The Italian Real Life Experience [J]. Curr Respir Med Rev，2017，13（1）：36-42.
[19] Korn S，Thielen A，Seyfried S，et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany [J]. Respir Med，2009，103（11）：1725-1731.
[20] Menzella F，Galeone C，Formisano D，et al. Real-life Efficacy of Omalizumab After 9 Years of Follow-up [J]. Allergy Asthma Immunol Res，2017，9（4）：368-372.
[21] Bousquet J，Siergiejko Z，Swiebocka E，et al. Persistency of response to omalizumab therapy in severe allergic（IgE-mediated）asthma [J]. Allergy，2011，66（5）：671-678.
[22] 奥玛珠单抗治疗过敏性哮喘专家组.奥玛珠单抗治疗过敏性哮喘的中国专家共识[J].中华结核和呼吸杂志，2018，41（3）：179-185.
[23] Casale TB，Chipps BE，Rosen K，et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma [J]. Allergy，2018，73（2）：490-497.
[24] Caminati M，Gatti D，Dama A，et al. Serum periostin during omalizumab therapy in asthma：A tool for patient selection and treatment evaluation [J]. Ann Allergy Asthma Immunol，2017，119（5）：460-462.
[25] Tajiri T，Matsumoto H，Gon Y，et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma [J]. Allergy，2016，71（10）：1472-1479.
[26] Bhutani M，Yang WH，Hebert J，et al. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma The ASTERIX Observational study [J]. PLoS One，2017，12（8）：e0183869.